ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc (GLUE)

5.93
0.24
(4.22%)
At close: September 09 4:00PM
5.93
-0.02
( -0.34% )
After Hours: 6:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
5.93
Bid
5.72
Ask
6.00
Volume
136,780
5.695 Day's Range 6.07
2.44 52 Week Range 8.84
Market Cap
Previous Close
5.69
Open
5.73
Last Trade
2
@
6
Last Trade Time
Financial Volume
$ 809,159
VWAP
5.9158
Average Volume (3m)
234,057
Shares Outstanding
61,372,824
Dividend Yield
-
PE Ratio
-2.70
Earnings Per Share (EPS)
-2.21
Revenue
-
Net Profit
-135.35M

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enable... Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Monte Rosa Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GLUE. The last closing price for Monte Rosa Therapeutics was $5.69. Over the last year, Monte Rosa Therapeutics shares have traded in a share price range of $ 2.44 to $ 8.84.

Monte Rosa Therapeutics currently has 61,372,824 shares outstanding. The market capitalization of Monte Rosa Therapeutics is $349.21 million. Monte Rosa Therapeutics has a price to earnings ratio (PE ratio) of -2.70.

GLUE Latest News

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines...

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases...

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial...

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines...

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose...

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.105-1.739850869936.0356.255.441619835.78079939CS
41.9548.99497487443.987.083.74112183855.88465039CS
122.1757.71276595743.767.083.212340574.5922022CS
26-0.44-6.907378335956.378.843.212075225.02216178CS
52-0.07-1.1666666666768.842.442191734.77214545CS
156-29.47-83.248587570635.436.642.442050288.99436761CS
260-16.07-73.04545454552245.562.4421012410.49450498CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NBSTWNewbury Street Acquisition Corporation
$ 0.08
(59.05%)
10.3k
SMMTSummit Therapeutics Inc
$ 19.13
(55.91%)
47.83M
ALGSAligos Therapeutics Inc
$ 19.50
(55.88%)
489.86k
SINTSiNtx Technologies Inc
$ 4.3242
(53.34%)
68.7M
TILInstill Bio Inc
$ 21.8001
(52.98%)
1.14M
EGIOEdgio Inc
$ 1.239
(-79.92%)
4.71M
PEGYPineapple Energy Inc
$ 0.292758
(-63.83%)
11.45M
WHLRWheeler Real Estate Investment Trust Inc
$ 6.6301
(-35.32%)
9.35M
HOVRNew Horizon Aircraft Ltd
$ 0.70
(-30.00%)
4.42M
WTOUTime Limited
$ 0.0469
(-28.94%)
257.25M
NVDANVIDIA Corporation
$ 106.47
(3.54%)
273.73M
WTOUTime Limited
$ 0.0469
(-28.94%)
257.25M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1633
(14.60%)
229.4M
SQQQProShares UltraPro Short QQQ
$ 9.36
(-3.70%)
168.89M
INBSIntelligent Bio Solutions Inc
$ 1.8199
(15.18%)
90.82M

Your Recent History

Delayed Upgrade Clock